1/3/07 from yahoo...American Oriental Bioengineering 'Posts Very Encouraging Q3FY06 Results,' 'Buy/4' Rating Reiterated, Target Raised To $12, In 'Institutional' Research Update By Investrend Analyst Lytel(paid for by AOB)
Wednesday January 3, 3:14 pm ET
NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) In a report dated November 30, 2006, American Oriental Bioengineering (AMEX: AOB - News) was as "Buy/4," with an increased target valuation of $12, beating analyst's expectations, reporting revenues of $27 million, net income of $7.6 million and EPS of $0.12 in an "Institutional" Update by Investrend analyst Kipley J. Lytel, CFA.
The full report, including important disclosures and disclaimers, is available at investrendresearch.com. In the report, the analyst also stated:
"The robust revenue growth stems both from acquisitions and from organic growth. AOB has been aggressively promoting its products, employing a Chinese celebrity for its advertising campaign, while acquisitions have helped expand the distribution network and product portfolio. The company reported that backlog for GLP's Jinji Series of products for Q4FY06 stood at $6 million.
"Two of AOB's products have been included in Chinese government's International Traditional Chinese Medicine Program for Cooperation in Science and Technology, which should provide the company with additional visibility factor and possibly will provide the company access to some government facilities or support. Also, the company has hired a new director, Lawrence S. Wizel, who has several decades of experience in Deloitte & Touche. Finally, AOB is moving its corporate headquarters, a move which in the long run may help the company better expand its business and control costs.
"As a result of the stellar growth and improved outlook, we have updated our valuation and price target, which has been increased to $12, representing gain potential of approximately 20%."
All Investrend Research reports published for AOB, including important disclosures and disclaimers, are also available via the company's InvestorPower(TM) Page, posted at Investrend.com (http://www.investrend.com). InvestorPower(TM) Pages are directly accessible from investrend.com. Investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.
AOB is enrolled in Investrend Research's pioneering professional research program, which facilitates independent analysts to provide coverage for shareholders in companies that otherwise would have little or no analyst following.
Enrollment fees for Institutional coverage were $36,890, and the fees have been paid by the company. Analysts are paid in advance of initial reports by Investrend Research to eliminate pecuniary interest, and neither the analyst nor anyone associated with Investrend Research may own or trade in the stocks of a company under coverage.
Investrend subscribes to the "Standards of Practice for Research Providers" at firstresearchconsortium.com, and its research is enrolled for investor monitoring by the not-for-profit Shareholders Research Alliance, Inc. (http://www.shareholdersresearch.com).
Anyone interested in receiving alerts regarding AOB research should email contact@investrend.com with "AOB" in the subject line.
Forward-Looking Statements: Statements in this news release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results. |
